Aztreonam is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Jing Zhou (1). The most-studied condition is Ceftazidime-avibactam. The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB
NCT07478484 · ClinicalTrials.gov ↗ · Ceftazidime-avibactam, Aztreonam, Gram-negative Bacterial Infection
|
Phase 4 | Recruiting | Jing Zhou | China |
|
Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.
NCT07204522 · ClinicalTrials.gov ↗ · Febrile Neutropenia
|
Observational | Recruiting | Shanxi Bethune Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Aztreonam. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
3 single-substance products containing Aztreonam on the HPRA medicines list.
| Lead sponsor | Trials |
|---|---|
| Jing Zhou | 1 |
| Shanxi Bethune Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
| EU register (CTIS) | 3 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our China register name Aztreonam as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Jing Zhou (1) and Shanxi Bethune Hospital (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 3 single-substance products containing Aztreonam, for example Cayston 75 mg powder and solvent for nebuliser solution. (Gilead Sciences Ireland UC). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
The registers we track list 2 entries for Aztreonam: Azactam (EU: shortage ongoing); 1 German notice. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Aztreonam works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Aztreonam works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Aztreonam (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.